Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate
Ultragenyx Pharmaceutical Q1 2024 GAAP EPS $(2.03) Misses $(1.77) Estimate, Sales $108.833M Miss $116.009M Estimate
Ultragenyx Pharmaceutical 2024年第一季度GAAP每股收益（2.03）未達到預期（1.77）美元，銷售額爲1.0833億美元，未達到1.16009億美元的預期
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(2.03) per share which missed the analyst consensus estimate of $(1.77) by 14.69 percent. The company reported quarterly sales of $108.833 million which missed the analyst consensus estimate of $116.009 million by 6.19 percent. This is a 8.30 percent increase over sales of $100.496 million the same period last year.
Ultragenyx Pharmaceutical（納斯達克股票代碼：RARE）公佈的季度每股虧損爲2.03美元，比分析師普遍預期的1.77美元（1.77美元）低14.69％。該公司公佈的季度銷售額爲1.08833億美元，比分析師普遍預期的1.16009億美元低6.19％。這比去年同期的1.00496億美元的銷售額增長了8.30％。